Allogene Therapeutics
Allogeneic CAR-T cell therapy platform with multiplex gene-engineering and gene-editing capabilities for cancer and autoimmune diseases
- Sector
- Biotech
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Founded
- 2017
- Latest Form D
- $412M, Apr 2018
- Total capital
- $412M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $412M
- 1 Form D · last Apr 2018
- 102 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 15
- 25 pending · first 2023
- Rank in peer group#100 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$412M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#100 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- ARIE M. BELLDEGRUNDirectorNamed in SEC Form D filings
- DAVID M. BONDERMANDirectorNamed in SEC Form D filings
- DAVID M. CHANGDirectorNamed in SEC Form D filings
- DAVID M. TANENExecutive OfficerNamed in SEC Form D filings
- FRANZ M. HUMERDirectorNamed in SEC Form D filings
- JOHN M. DEYOUNGDirectorNamed in SEC Form D filings
Show all 10 people
- JOSHUA A. KAZAMExecutive Officer, DirectorNamed in SEC Form D filings
- OWEN M. WITTEDirectorNamed in SEC Form D filings
- ROBERT M. ABRAHAMDirectorNamed in SEC Form D filings
- TODD M. SISITSKYDirectorNamed in SEC Form D filings
What it has protected
USPTO · 15 granted of 40- PendingMETHODS FOR ENHANCING TCRab+ CELL DEPLETION EFFICIENCYUSPTOApplication 19572670
- PendingChimeric Cytokine Receptors Comprising Tgf Beta Binding DomainsUSPTOApplication 19429975
- PendingChimeric Cytokine Receptors Bearing A PD-1 EctodomainUSPTOApplication 19551160
Show all 40 patent records
- METHODS FOR ENHANCING TCRab+ CELL DEPLETION EFFICIENCYSep 17, 2026 · Application 19572670Pending
- Chimeric Cytokine Receptors Comprising Tgf Beta Binding DomainsAug 27, 2026 · Application 19429975Pending
- Chimeric Cytokine Receptors Bearing A PD-1 EctodomainJul 9, 2026 · Application 19551160Pending
- Fasl Expression And Fasr Gene Knockout To Protect Therapeutic Cells From Allogeneic Rejection And Activation-induced Cell DeathJun 18, 2026 · Application 19543807Pending
- Selective Targeting Of Host CD70+ Alloreactive Cells To Prolong Allogeneic Car T Cell PersistenceMay 28, 2026 · Application 19420409Pending
- METHODS FOR ENHANCING TCRab+ CELL DEPLETION EFFICIENCYMay 14, 2026 · Application 19442909Pending
- Selective Targeting Of Host CD70+ Alloreactive Cells To Prolong Allogeneic Car T Cell PersistenceApr 30, 2026 · Application 19353269Pending
- Selective Targeting Of Host CD70+ Alloreactive Cells To Prolong Allogeneic Car T Cell PersistenceApr 23, 2026 · Application 19420431Pending
- KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTSMar 17, 2026 · US 12,577,283Granted
- Fasl Expression And Fasr Gene Knockout To Protect Therapeutic Cells From Allogeneic Rejection And Activation-induced Cell DeathMar 17, 2026 · US 12,577,290Granted
- Selective Targeting Of Host CD70+ Alloreactive Cells To Prolong Allogeneic Car T Cell PersistenceFeb 12, 2026 · Application 19363288Pending
- Chimeric Cytokine Receptors Comprising Tgf Beta Binding DomainsJan 20, 2026 · US 12,528,856Granted
- Methods For Transducing Immune CellsJan 8, 2026 · Application 19241275Pending
- Formulations And Processes For Car T Cell Drug ProductsDec 18, 2025 · Application 19179612Pending
- Inducible Chimeric Cytokine ReceptorsOct 30, 2025 · Application 18917035Pending
- Method Of Treatment Using ANTI-CD19 Rituximab-resistant Chimeric Antigen ReceptorsOct 21, 2025 · US 12,447,178Granted
- Methods For Transducing Immune CellsJul 22, 2025 · US 12,365,873Granted
- Chimeric Antigen Receptors With Enhanced Signaling And Activities And Uses ThereofJul 17, 2025 · Application 18987766Pending
- Methods For Detecting Genomic Abnormalities In CellsJun 26, 2025 · Application 18970541Pending
- Methods Of Manufacturing Allogeneic Car T CellsMay 29, 2025 · Application 18933228Pending
- Formulations And Processes For Car T Cell Drug ProductsMay 13, 2025 · US 12,295,362Granted
- Constitutively Active Chimeric Cytokine ReceptorsFeb 13, 2025 · Application 18741447Pending
- Chimeric Antigen Receptors With Enhanced Signaling And Activities And Uses ThereofFeb 4, 2025 · US 12,215,347Granted
- Modified CASPASE-9 Polypeptides And Methods Of Use ThereofDec 26, 2024 · Application 18821943Pending
- Inducible Chimeric Cytokine ReceptorsDec 10, 2024 · US 12,163,169Granted
- Methods Of Manufacturing Allogeneic Car T CellsDec 10, 2024 · US 12,163,153Granted
- Modified CASPASE-9 Polypeptides And Methods Of Use ThereofOct 1, 2024 · US 12,104,188Granted
- Constitutively Active Chimeric Cytokine ReceptorsJul 23, 2024 · US 12,043,655Granted
- Bcma Car-t Cells With Enhanced ActivitiesJul 16, 2024 · US 12,036,243Granted
- CD70 Anti-idiotype AntibodiesJul 11, 2024 · Application 18540202Pending
- mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLSJul 11, 2024 · Application 18481797Pending
- Method For Inhibiting Adventitious Viral InfectionMar 14, 2024 · Application 18450554Pending
- Polynucleotides Encoding Rituximab-resistant Chimeric Antigen ReceptorsFeb 13, 2024 · US 11,896,617Granted
- Engineered Cells With Reduced Gene Expression To Mitigate Immune Cell RecognitionFeb 8, 2024 · Application 18361056Pending
- Chimeric Cytokine Receptors Bearing A PD-1 EctodomainJan 18, 2024 · Application 18365014Pending
- Anti-talen Antibodies And Uses ThereofJan 4, 2024 · Application 18354037Pending
- Methods For Donor Cell AnalysisDec 21, 2023 · Application 18308797Pending
- Chimeric Switch Receptors For The Conversion Of Immunesuppressive Signals To Costimulatory SignalsNov 2, 2023 · Application 18191955Pending
- Chimeric Cytokine Receptors Bearing A PD-1 EctodomainOct 17, 2023 · US 11,786,553Granted
- Anti-talen Antibodies And Uses ThereofOct 10, 2023 · US 11,781,248Granted
Related companies, and why
- NEUMEDICINES, INC.Similar federal contract value in Biotech · null in contracts
- Zura Bio LtdSimilar federal contract value in Biotech · null in contracts
- Galecto, Inc.Similar federal contract value in Biotech · null in contracts
- RayzeBioSimilar federal contract value in Biotech · null in contracts
- ImvaxSimilar federal contract value in Biotech · null in contracts
- Zenas BioPharmaSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .